Fundraising Fox

TriWise Capital

Venture capital

Shenzhen · Pre-Seed–Late Stage · 1 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

TriWise Capital pursues a philosophy of 'investment returning to industry, capital serving industry,' emphasizing original and value investing across the healthcare ecosystem. It focuses on frontier technologies such as innovative drugs, cell and gene therapy, synthetic biology, biological breeding, and high-end medical devices. Leveraging partnerships with national medical device innovation centers, the Chinese Academy of Sciences Shenzhen Institute of Advanced Technology, and biomedical translation institutes, the firm targets early-stage companies with high growth potential and strong industry barriers. Its model combines roughly 30% investment with 70% services, effectively co-founding ventures with entrepreneurial teams and providing post-investment support to help commercialize scientific research results.

Source: firm website, verified Aug 3, 2026.

Stage
Pre-Seed–Late Stage
HQ
Shenzhen, CN
Leads rounds
Leads
Instruments
Equity
Founded
2015

Team · 1 people

from the firm's website
Tang Dajie· Founder

Dr. Tang Dajie is the founder of the firm and was recognized as one of the Top 10 outstanding investors in the Guangdong-Hong Kong-Macao Greater Bay Area science and innovation rankings.

Frequently asked questions

What stage does TriWise Capital invest at?
TriWise Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Late Stage stages.
What sectors does TriWise Capital focus on?
TriWise Capital focuses on Biotech, Climate Tech, Deep Tech, Digital Health, Healthtech, Medical Devices, Semiconductors.
Where is TriWise Capital located?
TriWise Capital is headquartered in Shenzhen, CN.
Does TriWise Capital lead rounds?
Yes, TriWise Capital leads investment rounds.

Similar investors

Featured in lists